✦ LIBER ✦

Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin

✍ Scribed by Rai Shimoyama; Hirofumi Yasui; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Kentaro Yamazaki; Keisei Taku; Takashi Kojima; Nozomu Machida; Akiko Todaka; Hideharu Tomita; Takeshi Sakamoto; Takahiro Tsushima

Publisher: Springer
Year: 2009
Tongue: English
Weight: 202 KB
Volume: 12
Category: Article
ISSN: 1436-3291
DOI: 10.1007/s10120-009-0524-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of irinotecan and docet

A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer

✍ Sun Jin Sym; Heung Moon Chang; Hye Jin Kang; Sung Sook Lee; Min-Hee Ryu; Jae-Lyu 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 336 KB

A phase I study of palliative chemoradia

A phase I study of palliative chemoradiation therapy with paclitaxel and cisplatin for local symptoms due to an unresectable primary advanced or locally recurrent gastric adenocarcinoma

✍ Takaki Yoshikawa; Akira Tsuburaya; Naoki Hirabayashi; Kazuhiro Yoshida; Naoki Na 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 287 KB

Impacts of fluorouracil-metabolizing enz

Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer

✍ Wasaburo Koizumi; Satoshi Tanabe; Mizutomo Azuma; Kenji Ishido; Ken Nishimura; T 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 267 KB

## Abstract A phase III trial of S‐1 plus cisplatin (SP) __versus__ S‐1 alone, for first‐line treatment of advanced gastric cancer (SPIRITS trial), has shown that overall survival was better in patients treated with SP than with S‐1 alone. In the present retrospective biomarker study, we aimed to d